Serum growth factors in asbestosis patients

Biomarkers

Volumn 14, Issue 1, 2009, Pages 61-66

  Li, Yongliang ^a   Karjalainen, Antti ^b   Koskinen, Heikki ^b   Vainio, Harri ^b   Pukkala, Eero ^c,d   Hemminki, Kari ^e   Brandt Rauf, Paul W ^a,f  

^a Columbia University ^*  (United States)

^b FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^c Institute for Statistical and Epidemiological Cancer Research   (Finland)

^d UNIVERSITY OF TAMPERE   (Finland)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

PDGF; Pneumoconiosis progression; Pneumoconiosis severity; TGF

Indexed keywords

PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

AGED; ARTICLE; ASBESTOSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; BLOOD; COHORT ANALYSIS; METABOLISM;

ASBESTOSIS; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PLATELET-DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

EID: 66149131097     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500802676868     Document Type: Article

References (36)

1. Auscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL.1993. Transforming growth factor ? as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 328:1592-1598.
2. Becklake MR, Bagatin E, Neder JA.2007. Asbestos-related diseases of the lungs and pleura: uses, trends and management over the last century. Int J Tuberc Lung Dis 11:356-369.
3. Border WA, Noble NA.1994. Transforming growth factor beta in tissue fibrosis. N Engl J Med 331:1286-1292.
4. Brandt-Rauf PW, Smith S, Hemminki K, Koskinen H, Vainio H, Niman H, Ford J.1992. Serum oncoproteins and growth factors in asbestosis and silicosis patients. Int J Cancer 50:881-885.
5. Brody AR. 1993. Asbestos-induced lung disease. Environ Health Perspect 100:21-30.
6. Brody AR.1997. Occupational lung disease and the role of peptide growth factors. Curr Opin Pulm Med 3:203-208.
7. Broekelman TJ, Limper AH, Colby TV, MacDonald JA.1991. Transforming growth factor-?1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci USA 88:6642-6646.
8. DiGiovine B, Lynch JP, Martinez FL.1996. The presence of pro-fibrotic cytokines correlate with outcome in patients with idiopathic pulmonary fibrosis. Chest 109:24S.
9. DiMari SJ, Howe AM, Haralson MA.1991. Effects of transforming growth factor-? on collagen synthesis by fetal rat lung epithelial cells. Am J Respir Cell Mol Biol 4:455-462.
10. Edwards DR, Murphy G, Reynolds JJ, Whitman SE, Docherty AJ, Angel P, Heath JK.1987. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 7:1899-1904.
11. Ford J, Smith S, Luo JC, Friedman-Jimenez G, Brandt-Rauf P, Markowitz S, Garabaldi K, Niman H.1992. Serum growth factors and oncoproteins in firefighters. Occup Med (Lond) 42:39-42.
12. Gharaee-Kermani M, Denholm EM, Phan SH.1996. Costimulation of fibroblast collagen and transforming growth factor beta 1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 271:12229-12284.
13. Husgafvel-Pursiainen K, Kannio A, Oksa P, Suitiala T, Koskinen H, Hemminki K, Smith S, Rosenstock-Leibu R, Brandt-Rauf PW. 1997. Mutations, tissue accumulations and serum levels of p53 in patients with occupational cancers from asbestos and silica exposure. Environ Mol Mutagen 30:224-230.
14. Ignotz RA, Massague J.1986. Transforming growth factor-? stimulates the expression of fibronectin and collagen and their incorporation into extracellular matrix. J Biol Chem 261:4337-4345.
15. Jagirdar J, Begin R, Dufresne A, Goswami S, Lee TC, Rom WN.1996. Transforming growth factor ? in silicosis. Am J Respir Crit Care Med 154:1844-1847.
16. Jagirdar J, Lee TC, Reibman J, Gold LI, Aston C, Begin R, Rom WN.1997. Immunohistochemical localization of transforming growth factor beta isoforms in asbestos-related diseases. Environ Health Perspect 105:1197-1203.
17. Khalil N, O'Connor RN, Unruh HW, Warren PW, Flanders KC, Kemp A, Bereznay OH, Greenberg AH. 1991. Increased production and immunohistochemical localization of transforming growth factor-? in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 5:155-162.
18. Lee TC, Gold LI, Reibman J, Aston C, Begin R, Rom WN, Jagirdar J. 1997. Immunohistochemical localization of transforming growth factor-? and insulin-like growth factor-I in asbestosis in the sheep model. Int Arch Occup Environ Health 69:157-164.
19. Li Y, Karjalainen A, Koskinen H, Hemminki K, Vainio H, Shnaidman M, Ying Z, Pukkala E, Brandt-Rauf PW.2005. p53 autoantibodies predict subsequent development of cancer. Int J Cancer 114:157-160.
20. Lin RT, Takahashi K, Karjalainen A, Hoshuyama T, Wilson D, Kameda T, Chen CC, Wen CP, Furuya S, Higashi T, Chien LC, Ohtaki M.2007. Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet 369:844-849.
21. Liu JY, Brody AR.2001. Increased TGF-beta1 in the lungs of asbestosexposed rats and mice: reduced expression in TNF-alpha receptor knockout mice. J Environ Pathol Toxicol Oncol 20:97-108.
22. Maniscalo WM, Campbell MH.1994. Transforming growth factorbeta induces a chondroitin sulfate/dermatan sulfate proteoglycan in alveolar type II cells. Am J Physiol 266:L672-L680.
23. Mariani TJ, Roby JD, Mecham RP, Parks WC, Crouch E, Pierce RA. 1996. Localization of type I procollagen gene expression in silica-induced granulomatous lung disease and implication oftransforming growth factor-beta as a mediator of fibrosis. Am J Pathol 148:151-164.
24. Massague J, Chiefitz S, Laiho M, Ralph DA, Weis FMB, Zentella A. 1992. Transforming growth factor-?. Cancer Surv 12:81-103.
25. Mossman BT, Kamp DW, Weitzman SA.1996. Mechanisms of carcinogenesis and clinical features of asbestos-associated cancer. Cancer Invest 14:466-480.
26. Oksa P, Pukkala E, Karjalainen A, Ojajarvi A, Huuskonen MS.1997. Cancer incidence and mortality among Finnish asbestos sprayers and in asbestosis and silicosis patients. Am J Ind Med 31:693-698.
27. Oksa P.1998. Asbestosis, Its Detection, and Predictors of Progression and Cancer. Helsinki: Finnish Institute of Occupational Health.
28. O'Reilly KMA, McLaughlin AM, Beckett WS, Sime PJ.2007. Asbestosrelated lung disease. Am Fam Physician 75:683-688.
29. Partanen R, Hemminki K, Koskinen H, Luo JC, Carney WP, Brandt- Rauf PW.1994. The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients. J Occup Med 36:1324-1328.
30. Perdue TD, Brody AR.1994. Distribution of transforming growth factor-beta 1, fibronectin, and smooth muscle actin in asbestos- induced pulmonary fibrosis in rats. J Histochem Cytochem 42;1061-1070.
31. Polyak K.1996. Negative regulation of cell growth by TGF beta. Biochim Biophys Acta 1242:185-189.
32. Robledo R, Mossman B.1999. Cellular and molecular mechanisms of asbestos-induced fibrosis. J Cellular Physiol 180:158-166.
33. Teppo L, Pukkala E, Lehtonen M.1994. Data quality and quality control of a population-based cancer registry. Acta Oncol 33:365-369.
34. Vanhee D, Gosset P, Wallaert B, Voisin C, Tonnel AB.1994. Mechanisms of fibrosis in coal workers' pneumoconiosis: increased production of platelet-derived growth factor, insulin-like growth factor type I, and transforming growth factor beta and relationship to disease severity: clinical relevance of cellular mediators of inflammation in workers exposed to asbestos. Am J Respir Crit Care Med 150:881-885.
35. Yao W, Feng FF, Jiao J, Wang N.2006. Expression level and significance of TGF-beta1, PDGF, CTGF in serum of patients with pneumoconiosis. Sichuan Da Xue Xue Bao Yi Xue Ban 37:754-756.
36. Yoshida M, Sakuma J, Hayashi S, Abe K, Saito I, Harada S, Sakatani M, Yamamoto S, Matsumoto N, Kaneda Y, Kishimoto T.1995. A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor beta 1, or platelet derived growth factor B gene. Proc Natl Acad Sci USA 92:9570-9574.